3M’s $7.35 Billion AFFF Settlement: What PFAS Personal Injury Lawyers Need to Know

For years, the AFFF personal injury litigation has been marked by a significant gap, by means of thousands of claimants, but no jury verdict. A bellwether trial was scheduled, then vacated, with no replacement date in sight. This changed on November 3, 2026, when 3M announced a settlement intended to resolve most PFAS-related personal injury claims in the AFFF multidistrict litigation (MDL).[1]
According to 3M, the agreement addresses approximately 99% of current personal injury claims, both inside and outside the MDL, potentially covering 115,000 to 120,000 plaintiffs. Emerging from a previously disclosed mediation process, it represents one of the largest resolutions in modern toxic tort history.[2] However, the headline figure alone does not tell the whole story.
Understanding the $7.35 Billion Figure
The $7.35 billion represents 3M’s total nominal commitment over nine years, from 2026 through 2034. Its present value is approximately $5.8 billion, which the company expects to record as a pretax charge in the fourth quarter of 2026. These figures reflect the same financial commitment, measured differently. Neither represents an individual claimant’s expected recovery.[3]
The payment schedule includes $50 million in 2026, no scheduled payment in 2027, and approximately 20% of payments during the final two years. A $680 million reserve fund is also included in the overall commitment. Importantly, payments depend on plaintiffs participating in the settlement.[4]
Individual recoveries will depend on allocation procedures and claims requirements that have not yet been made public. Firms should therefore avoid giving clients specific settlement expectations at this stage.
Who Is Eligible?
The settlement covers six qualifying injuries, namely kidney cancer, testicular cancer, liver cancer, thyroid cancer, ulcerative colitis, and thyroid disease. These six conditions have been identified by Judge Gergel in Case Management Order No. 33, which sets out the complete list of injuries the Plaintiffs’ Executive Committee sought to pursue in the MDL.[5]
Having one of the qualifying diagnoses does not automatically make an individual eligible for the settlement. They must also meet the applicable exposure criteria and provide the necessary supporting documentation. Individuals diagnosed with other conditions potentially associated with PFAS exposure, such as pancreatic or prostate cancer, should not assume that they are covered by the agreement. [6]
What Claimants Give Up by Participating
Participation comes with an important consideration that claimants must provide 3M with a full release of PFAS-related personal injury claims, including certain claims already asserted or that could be brought in the future. [7]
The release may extend beyond the specific illness qualifying the claimant for compensation. Someone who later develops another PFAS-related condition could find that the related claim has already been released. Attorneys should therefore consider the client’s broader medical history and potential future claims before recommending enrolment.
3M may also terminate the agreement if participation falls below specified thresholds. The company has not admitted liability or wrongdoing and maintains that it is prepared to continue defending the litigation if the settlement conditions are not satisfied. [8]
What Happens to Those Who Opt Out?
On November 4, Judge Gergel issued orders addressing claimant identification and litigation against 3M, setting November 13 as the deadline for identifying eligible claimants. [9] With that date now reached, firms should verify compliance and address any outstanding identification issues immediately.
The agreement also anticipates an MDL court order establishing evidentiary and timing requirements for plaintiffs who continue litigating. CMO No. 40 addresses these requirements. Non-participants should expect tighter deadlines and more demanding proof requirements. Opting out, therefore, means weighing not only the settlement amount but also the cost and risk of pursuing litigation independently. [10]
What the Settlement Does Not Cover
The agreement does not bring PFAS litigation to an end. Manufacturers such as DuPont, Chemours and Corteva continue to face separate lawsuits, and 3M’s settlement does not release claims against them. [11]
Water-provider claims are also outside its scope. 3M’s 2023 resolution with U.S. public water suppliers, which carried a present-value commitment of approximately $10.3 billion, addressed drinking water contamination, testing, treatment and remediation rather than this personal injury settlement. [12]
For remaining and future personal injury claims, 3M has identified mechanisms including the reserve fund and the anticipated court order. Following its earlier water-provider resolution and a more recent settlement with New Jersey, the company appears to be continuing its broader strategy of addressing legacy PFAS litigation through separate resolutions. [13]
What PI Firms Should Be Doing Now
For firms managing AFFF inventories, the immediate priority is claimant-specific eligibility and documentation. Firms must start by confirming that all potentially eligible clients were identified under the November 4 orders and review each file against the six qualifying injuries and flag cases involving conditions outside the list.
Next, the exposure record should be strengthened. Military service, firefighting, airport employment and other occupational histories may help establish when and how AFFF exposure occurred, even when the events date back decades.
Medical documentation deserves equal attention. Pathology reports, diagnostic records and treatment histories should be complete and properly organized. Preparing a medical chronology for each claimant can help identify missing records before enrolment begins.
Finally, the firms should explain the release carefully, particularly its potential effect on future PFAS-related claims and monitor upcoming court orders for enrolment procedures and deadlines.
Looking Ahead
The settlement gives the AFFF personal injury litigation a resolution framework after years without a trial or verdict. However, payments will take time, the 2027 schedule includes no payment, and several important claims procedures remain outstanding.
For attorneys, the next phase will require careful file review, reliable exposure documentation and informed client decisions. Ultimately, the firms best prepared for this transition will be those that can establish each claimant’s eligibility accurately while ensuring clients understand what participation involves.
[1] 3M Co., Current Report (Form 8-K), Items 1.01, 8.01
https://www.sec.gov/Archives/edgar/data/66740/000006674026000318/pressrelease-xnov2026xv2.htm
[2] 3M Co., 3M Reaches Broad Resolution of AFFF Personal Injury Litigation
https://www.sec.gov/Archives/edgar/data/66740/000006674026000318/mmm-20261103.htm
[3] 3M Co., Current Report (Form 8-K), Items 1.01, 8.01
[4] Master Settlement Agreement §§ 5, 11, In re Aqueous Film-Forming Foams Prods. Liab. Litig., MDL No. 2:18-mn-2873-RMG
https://www.sec.gov/Archives/edgar/data/66740/000006674026000318/msa.htm
[5] Case Management Order No. 33 at 1, In re Aqueous Film-Forming Foams Prods. Liab. Litig., MDL No. 2:18-mn-2873-RMG, ECF No. 6863
https://www.robertkinglawfirm.com/wp-content/uploads/2025/04/case-management-order-33-afff-pfas-military-drinking-water-lawsuit-injury-claims.pdf
[6] Master Settlement Agreement, supra note 4.
[7] Master Settlement Agreement §§ 3, 3.2, supra note 4.
[8] Master Settlement Agreement §§ 5, 11, supra note 4.
[9] Case Management Order No. 39, In re Aqueous Film-Forming Foams Prods. Liab. Litig., MDL No. 2:18-mn-2873-RMG, ECF No. 11962
https://nighgoldenberg.com/wp-content/uploads/2026/11/MDL-2873-Aqueous-Film-Forming-Foams-AFFF-Products-Liability-Litigation-Case-Management-Order-No-39-Identification-Order-for-Eligible-Personal-Injury-Claimants-Under-3M-Settlement-Agreement.pdf
[10] Case Management Order No. 40, In re Aqueous Film-Forming Foams Prods. Liab. Litig., MDL No. 2:18-mn-2873-RMG, ECF No. 11964
[11] Master Settlement Agreement, supra note 4.
[12] Settlement Agreement Between Public Water Systems and 3M Co. (June 22, 2023), filed as Exhibit 10.1 to 3M Co., Current Report (Form 8-K)
https://www.sec.gov/Archives/edgar/data/66740/000006674023000048/ex101publicwssa.htm
[13] 3M Co., 3M Reaches Broad Resolution of AFFF Personal Injury Litigation.
https://news.3m.com/2026-11-03-3M-Reaches-Broad-Resolution-of-AFFF-Personal-Injury-Litigation
